Insight Capital Research & Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Insight Capital Research & Management’s Portfolio KERX Stock Details KERX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-587,504	Closed	-$10M	–	162
2014 Q1	$10M	Sell	587,504 -272,168	-32%	-$4.11M	2.31%	2
2013 Q4	$11.1M	Sell	859,672 -600,266	-41%	-$7.17M	2.5%	2
2013 Q3	$15.1M	Sell	1,459,938 -133,730	-8%	-$1.19M	3.66%	1
2013 Q2	$11.9M	Buy	+1,593,668	New	+$12.5M	3.09%	3

Other funds holding KERX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Insight Capital Research & Management's KERX Position: Q2 2014 in Review

Insight Capital Research & Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2014, closing a stake of 587,504 shares — an estimated $10M sold.

Insight Capital Research & Management first reported a position in KERX in Q2 2013 and held it in 4 quarters. The position peaked at $15.1M in Q3 2013. 135 funds tracked by Wall St. Rank hold KERX as of Q2 2014.

Insight Capital Research & Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2014 after selling out during the quarter.
Insight Capital Research & Management sold 587,504 Keryx Biopharmaceuticals Inc shares in Q2 2014, an estimated $10M.
Insight Capital Research & Management first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 4 quarters.
Insight Capital Research & Management's Keryx Biopharmaceuticals Inc position peaked at $15.1M in Q3 2013.
135 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2014.

Based on Insight Capital Research & Management's 13F filing for Q2 2014, filed 13 Aug 2014.